Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simethicone for disorders of gut-brain interaction
ACTRN12624000663550Phase 3Not yet recruiting
- Sponsor
- Metro South Health
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of simethicone in functional gastrointestinal disorder (FGID) (3 arms), sponsored by Metro South Health. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
simethicone
03
Conditions
functional gastrointestinal disorder (FGID)
Beyond the preview
Go deeper on ACTRN12624000663550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000663550.